4174.TWO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 01:30):

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally...

Stats
Today's Volume	140 627
Average Volume	440 314
Market Cap	13.57B
EPS	TWD0 ( 2024-03-13 )
Next earnings date	( TWD0 ) 2024-05-05
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-12.95
ATR14	TWD0.0590 (0.10%)

Volume Correlation

Long: 0.02 (neutral)

Short: 0.00 (neutral)

Signal:(53.01) Neutral

OBI Pharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OBI Pharma, Inc. Correlation - Currency/Commodity

0.46
( neutral )

0.55
( weak )

0.00
( neutral )

0.65
( weak )

0.04
( neutral )

0.27
( neutral )

OBI Pharma, Inc. Financials

Annual	2023
Revenue:	TWD41.55M
Gross Profit:	TWD-73.50M (-176.89 %)
EPS:	TWD-5.53

Q4	2023
Revenue:	TWD18.42M
Gross Profit:	TWD-14.21M (-77.14 %)
EPS:	TWD-2.47

Q3	2023
Revenue:	TWD11.48M
Gross Profit:	TWD-21.46M (-187.00 %)
EPS:	TWD-2.48

Q2	2023
Revenue:	TWD9.87M
Gross Profit:	TWD-18.60M (-188.49 %)
EPS:	TWD1.790

Financial Reports:

No articles found.

OBI Pharma, Inc.

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.